Rancho Santa Fe Bio, Inc ("RSF Bio") is a clinical-stage, cardiovascular therapeutics platform company, based in San Diego, California.
Calcific aortic Valve Stenosis (CAVS) affects 3% of the population over 65 and is characterized by the progressive accumulation of calcium on the aortic valve.
Currently, there are no therapeutic approaches for slowing the progression of CAVS, which eventually leads to valve replacement (TAVR/SAVR), with most patients undergoing watchful waiting.
Ataciguat is a small molecule drug developed to slow the progression of CAVS and delay surgical valve replacement.
Since CAVS is a common valvular disease in the elderly, the market for ataciguat is approximately 2 million people in the U.S., over 3 million in Europe, and potentially more throughout the rest of the world.
RSF Bio is engaged in discussions for the licensing in, and the development of, next generation technology for additional applications in the field of cardiovascular disease. Please visit our Science and Pipeline pages for more information.
Copyright © 2021 RSF Bio - All Rights Reserved.